Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Karyopharm Therapeutics Inc. (the "Company") announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S. XPOVIO® (selinexor) net product revenue estimates, and outlined its 2022 achievements and 2023 objectives. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



The following exhibit relating to Item 2.02 shall be deemed to be furnished, and
not filed:

               99.1      Press release issued by Karyopharm Therapeutics Inc. on January
                       9, 2023

               104     Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses